GBT Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Global Blood Therapeutics (GBT) will engage in virtual fireside chats at two investor conferences: the SVB Leerink 10th Annual Global Healthcare Conference on February 26 at 2:20 p.m. ET and the Cowen 41st Annual Health Care Conference on March 1 at 11:40 a.m. ET. CEO Ted W. Love will also participate in a panel on Non-Malignant Hematology on March 1 at 2:40 p.m. ET. The events will be available live on GBT’s website, with replays archived for a month after each conference.

GBT focuses on treatments for sickle cell disease, having developed Oxbryta®, the first FDA-approved treatment for this condition.

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences:

• SVB Leerink 10th Annual Global Healthcare Conference on February 26 at 2:20 p.m. ET; and
  
• Cowen 41st Annual Health Care Conference on March 1 at 11:40 a.m. ET. Ted W. Love, M.D., president and CEO of GBT, will also participate in a virtual panel, Non-Malignant Hematology, at this conference on March 1 at 2:40 p.m. ET.

The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcasts will be archived and available for one month following each event.

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650.410.3258
simmergut@gbt.com

Courtney Roberts (investors)
650.351.7881
croberts@gbt.com

FAQ

What conferences is Global Blood Therapeutics participating in February 2021?

GBT is participating in the SVB Leerink 10th Annual Global Healthcare Conference on February 26 and the Cowen 41st Annual Health Care Conference on March 1.

Who will represent GBT at the investor conferences?

Ted W. Love, M.D., the president and CEO of GBT, will represent the company.

What is the focus of GBT's drug development?

GBT focuses on developing treatments for sickle cell disease.

How can I access the webcasts of GBT's investor conferences?

The webcasts will be live on GBT's website and available for replay for one month after the events.

What is Oxbryta® developed by GBT?

Oxbryta® is the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, addressing the root cause of sickle cell disease.